Learn about a treatment option for metastatic colorectal cancer and an initial treatment option for locally or regionally advanced head and neck cancer.

Colon Cancer:
ERBITUX (Cetuximab) is indicated for the treatment of patients who have colorectal cancer that has spread to other parts of the body and whose tumor expresses a protein called an Epidermal Growth Factor Receptor (EGFR).

Head & Neck Cancer:
ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the initial treatment of a certain type of locally or regionally advanced head and neck cancer.

This entry was posted on December 12, 2008 at 7:49 am and is filed under Cancer. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.